1-800-710-4674

Blog Post

Return to News

Feature Story

 
lung cancer clinical trials

OHC Studies Drug That May Become a New First-Line Treatment for Lung Cancer

Cynthia Chua, MD, OHC Medical Oncologist and Hematologist, Blogs, 0 comments
April 18, 2019

 

Cynthia Chua MD OHC medical oncologistWhen a patient hears the word cancer, they want to know they have access to the latest treatments available to fight their cancer. When you choose OHC doctors, you have access to their nationally recognized clinical trials and the most promising treatment. The program provides patients with access to new, innovative treatments that are not available any other way.

OHC has open trials for bladder, blood, breast, anal, esophageal, gastrointestinal, kidney, lung, lymphoma, ovarian, pancreas, prostate and solid tumors. OHC understands the importance of clinical trials in the treatment of cancer because we know that the day we find a cure for cancer, it will be found through a clinical trial.

“I chose to participate in a clinical trial for two reasons,” said OHC lung cancer survivor J.P. Hiereman. “One, there was a possibility [the drug being tested] would be better than what I was doing. They’re not going to develop a drug that isn’t as good as something they already have. Also, this gave my cancer a meaning, a purpose. If they could find something through me that would help others, that was a great plus.”

OHC has participated in trials that have significantly improved the lives of patients. A study currently underway at OHC is for patients with AKL-positive non-small cell lung cancer that is testing a drug called brigatinib versus a drug called alectinib.

The two drugs have much in common. Both drugs have demonstrated to benefit people with ALK-positive NSCLC. Both drugs belong to a class of drugs called ALK inhibitors, and are considered “next generation” ALK-inhibitors. Both drugs are taken by mouth and both are approved by the US Food and Drug Administration.

Brigatinib has previously demonstrated the longest progression free survival (the time that a patient can live with a cancer without it getting worse) of any next generation ALK inhibitor – when given immediately after crizotinib. OHC is studying Brigatinib to see if it works just as well as for patients when it’s a first-line treatment.

Learn more about J.P.’s clinical trial experience from his video. You can also learn about clinical trials from OHC’s David M. Waterhouse, MD, Co-Director of OHC’s Research Department here. For a list of open trials, go to this page or if you’d like a second opinion about your cancer diagnosis, call OHC at 1-800-710-4674.

 
 

Leave a Reply

Your email address will not be published. Required fields are marked *